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Long-term predictors of mortality in ICD patients with
non-ischaemic cardiac disease: impact of renal function
Abstract
BACKGROUND: Randomized trials have demonstrated that implantable cardioverter defibrillator
(ICD) therapy may reduce the risk of death in patients with non-ischaemic cardiomyopathy (CMP). In
this study, we aimed at determining the long-term benefit of ICD therapy among patients with dilated
CMP (DCM) and among those with other non-ischaemic cardiac diseases (NICDs). METHODS AND
RESULTS: We performed a single-centre longitudinal study to assess the outcomes of 176 patients with
NICDs who were implanted with an ICD for primary or secondary prevention of cardiac death. The
cumulative survival rate after 1, 2, 5, and 10 years was 91, 87, 78, and 65%, respectively. Mortality risk
did not differ significantly between patients with DCM and those with other NICDs. Atrial fibrillation,
recurrent ventricular arrhythmias requiring ICD therapy, and right ventricular pacing, but not delayed
intrinsic ventricular conduction, were associated with higher risk. New York Heart Association (NYHA)
functional class > or =III was an independent predictor of adverse outcome among patients with DCM
[hazard ratio (HR) 5.27, P = 0.01], whereas reduced left ventricular function with ejection fraction
<35% (HR 12.1, P < 0.001) and anti-arrhythmic drug use (HR 4.82, P = 0.03) were independent
predictors among those with other NICDs. Renal insufficiency with estimated glomerular filtration rate
<60 mL/min/1.73 m(2) (HR 5.9, P < 0.001) was a strong independent predictor of mortality among all
patients with NICD, irrespective of underlying cardiac condition. CONCLUSION: In ICD patients with
DCM, higher NYHA functional class is associated with adverse outcomes. Impaired left ventricular
function and anti-arrhythmic drug use predict higher mortality among patients with non-dilated, NICDs.
Impaired renal function is a strong predictor of mortality in all patients with NICD.
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ABSTRACT 
Background 
Randomized trials have demonstrated that implantable cardioverter defibrillator (ICD) therapy 
may reduce the risk of death in patients with nonischemic cardiomyopathy. In this study we 
aimed to determine the long-term benefit of ICD therapy among patients with dilated 
cardiomyopathy (CMP) and among those with other nonischemic cardiac diseases. 
Methods 
We performed a single-center longitudinal study to assess the outcomes of 176 patients with 
nonischemic cardiac diseases who were implanted with an ICD for primary or secondary 
prevention of cardiac death.  
Results 
The cumulative survival rate after 1, 2, 5 and 10 years was 91%, 87%, 78%, and 65%, 
respectively. Mortality risk did not differ significantly between patients with dilated 
cardiomyopathy and those with other nonischemic cardiac diseases. Atrial fibrillation, 
recurrent ventricular arrhythmias requiring ICD therapy, and right ventricular pacing, but not 
delayed intrinsic ventricular conduction was associated with higher risk. NYHA functional 
class ≥ III was an independent predictor of adverse outcome among patients with dilated 
cardiomyopathy (HR 5.27, p = 0.01), whereas reduced left ventricular function with ejection 
fraction <35% (HR 12.1, p < 0.001), and antiarrhythmic drug use (HR 4.82, p = 0.03) - 
among those with other nonischemic cardiac diseases.  
    
 
Renal insufficiency with estimated glomerular filtration rate < 60ml/min/1.73m² (HR 5.9, p < 
0.001) was a strong independent predictor of mortality among all patients with nonischemic 
cardiac disease, irrespective of underlying cardiac condition. 
Conclusion 
In ICD patients with dilated cardiomyopathy higher NYHA functional class is associated with 
adverse outcome. Impaired left ventricular function and antiarrhythmic drug use predict 
higher mortality among patients with nondilated, nonischemic cardiac diseases. Impaired 
renal function is a strong predictor of mortality in all patients with nonischemic cardiac 
disease. 
 
 
Key words: Implantable cardioverter defibrillator; nonischemic heart disease; mortality; 
sudden cardiac death; renal insufficiency.
 1 
Introduction 1 
Implantable cardioverter-defibrillator (ICD) therapy has been adopted in current guidelines 2 
for use in patients with coronary artery disease and in those with nonischemic 3 
cardiomyopathy.[1;2] While randomized controlled trials provide the best evidence about the 4 
scientific value of medical interventions, they may not always reflect clinical reality. Patient 5 
selection and stringent follow-up schedules may compromise estimation of the benefit for a 6 
patient which may be achieved under everyday clinical conditions. Clinical registries can help 7 
to overcome these limitations by providing long-term follow-up and supplemental data of 8 
patients who are generally not included in randomized controlled trials. In patients with ICDs, 9 
appropriate therapies and complications may occur even years after device implantation. 10 
Information derived from long-term studies may help the clinician to select which patients 11 
will benefit most and least from ICD treatment and may influence decisions about device 12 
replacement after battery depletion. Most randomized controlled trials of ICD-recipients with 13 
nonischemic cardiac disease have included primarily patients with dilated cardiomyopathy 14 
and have excluded patients with other nonischemic cardiac diseases, including valvular 15 
disease, hypertrophic and other nondilated cardiomyopathies as well as primary electric 16 
disorders.[3-5] The aim of the current study was to investigate the rate and determining 17 
factors of mortality during long-term follow-up of patients with nonischemic dilated 18 
cardiomyopathy (DCM) and with other nonischemic cardiac diseases (NICD) who had been 19 
implanted with an ICD for primary or secondary prevention of sudden cardiac death.  20 
 21 
Methods 22 
We performed a longitudinal study of consecutive patients with nonischemic cardiac disease 23 
who underwent both ICD implantation and device follow-up at the University Hospital 24 
 2 
Zurich. The study was conducted according to the institutional and regional ethics guidelines. 1 
Patients were excluded from the study if they received postimplantation care at another 2 
institution or if they were lost to follow-up. Patients implanted with a device for cardiac 3 
resynchronization therapy with defibrillator (CRT-D) were not included in this study. 4 
Baseline characteristics including patient history, clinical parameters, 5 
electrocardiogram, indication for ICD implantation, and device-related parameters of all 6 
patients were collected at the time of implantation and during follow-up visits. Comorbidities 7 
such as diabetes and hypertension were considered to be present if the diagnosis had been 8 
established previously by referring physicians or if disease-specific therapies were required. 9 
Renal function was determined by estimation of the glomerular filtration rate (eGFR) using 10 
the Modification of Diet in Renal Disease (MDRD) equation.[6] According to the definition 11 
of the National Kidney Foundation, [7] reduced renal function was defined as eGFR less than 12 
60ml/min/1.73m² of body-surface area.  13 
All patients attended regular follow-up visits at our ICD outpatient clinic, which were 14 
scheduled at three to six-month intervals. Additional appointments were made in case of ICD 15 
shock delivery or in the presence of new symptoms, according to patients’ requirements. A 16 
full interrogation of the device’s memory, including programmed parameters, stored 17 
measurements and electrograms, pacing threshold and sensing tests, and evaluation of 18 
appropriate device programming was performed at each visit. Device programming was 19 
individualized according to the patients’ underlying cardiac disease and tachycardia 20 
characteristics. Bradycardia pacing parameters were programmed to allow for intrinsic rhythm 21 
whenever possible. Right ventricular pacing was considered to be present in patients with a 22 
proportion of ventricular pacing 50% or more. Anti-tachycardia therapies were enabled in all 23 
patients. Mortality data were collected from hospital charts, primary care physicians, and 24 
from the patients’ families.  25 
 3 
Statistical analysis was performed with SPSS Version 13 for Windows (SPSS Inc, 1 
Chicago, IL). All analyses were performed for the overall group and for two subgroubs: 2 
patients with DCM and patients with other underlying cardiac conditions (nondilated NICD 3 
group) including all diagnoses listed in table 2. Descriptive statistics were performed for the 4 
analysis of baseline variables. Categorical data are presented as frequencies (%), continuous 5 
variables are presented as mean (SD). Time to death was plotted using the Kaplan-Meier 6 
method, and differences between groups were compared by the log-rank statistic. Univariate 7 
Cox regression analysis was used to determine hazard ratios for various pre-specified clinical 8 
factors, including age, sex, blood pressure, heart rate, left ventricular function, 9 
electrocardiographic characteristics, underlying cardiac disease, family history of cardiac 10 
death, antiarrhythmic drug use, proportion of right ventricular pacing, diabetes mellitus and 11 
renal function. All clinical factors were assessed at the time of device implantation. Serial 12 
measurements during follow-up were not available. A multivariate Cox regression model was 13 
used to identify independent predictors of mortality. Forward stepwise regression was 14 
performed with a probability of 0.5 for entry and 0.1 for removal from the model. For the 15 
regression analysis, the use of amiodarone and sotalol was combined in a single variable 16 
(antiarrhythmic drugs). A two-sided P value < 0.05 was considered statistically significant.  17 
Results 18 
Between January 1995 and April 2006, 481 patients were implanted with an ICD in the 19 
University Hospital of Zurich. Of those, 294 patients had coronary artery disease. Eleven 20 
patients moved away and were lost to follow-up. The remaining 176 patients (78% male, age 21 
20-80 years) with nonischemic cardiac disease were included in the analysis. In 40 patients 22 
(23%), an ICD was implanted for primary prevention of sudden cardiac death (SCD) without 23 
electrocardiographic documentation of a sustained ventricular arrhythmia prior to device 24 
 4 
implantation. In 136 patients (77%), an ICD was implanted for a secondary prevention 1 
indication. Of those, 41 (30%) had survived sudden cardiac death, 92 (68%) had experienced 2 
syncope or presyncope with spontaneous documented ventricular arrhythmia, 2 (2%) had no 3 
spontaneous VT, but inducible VT during electrophysiologic study, and one patient with 4 
hypertrophic cardiomyopathy had stress-induced syncope, but no documented ventricular 5 
arrhythmia. Baseline characteristics of the studied patients are presented in tables 1 and 2.  6 
During a mean follow-up time of 51 months (SD, 39; range 1 - 142), 76 patients (43%) 7 
experienced adequate ICD therapies, and 32 patients (18%) died. The estimated mean survival 8 
time was 105 (standard error (SE), 5) months. The cumulative survival rate after 1 year was 9 
91% (SE, 2%), after 2 years 87% (3%), after 4 years 84% (3%) after 5 years 78% (4%) and 10 
after 10 years 65% (6%). Survival rates did not differ significantly among patients with DCM 11 
compared with those with nondilated NICD (estimated mean survival time 93 (SE, 9) vs. 111 12 
(6) months p = 0.07). 13 
The overall survival time did not differ significantly among patients who had received 14 
an ICD for secondary prophylaxis compared with those who had a primary prevention 15 
indication for ICD implantation (66 (SE, 10) vs 110 (5) months; p = 0.1). In the primary 16 
prevention group, a higher rate of deaths occurred during the first two years following ICD 17 
implantation compared to the secondary prevention group. This could be observed among 18 
patients with DCM (Figure 1, left panel) as well as in those with other nonischemic cardiac 19 
diseases (right panel).  20 
Univariate predictors of mortality are presented in table 3. Patients who were younger 21 
than 55 years had better survival compared with those who were older at the time of ICD 22 
implantation. In contrast, advanced age was only weakly associated with increased mortality 23 
among those who were older than 55 years. Accordingly, there was no significant difference 24 
in survival time among patients older than 70 years compared with those aged 55 - 70 years (p 25 
 5 
= 0.4). Estimated survival time of patients younger than 55 years, 55-69 years and those aged 1 
70 years or older was 108 (SE, 13), 92 (14) and 56 (10) months in patients with DCM (p = 2 
0.23),  and 128 (5), 69 (9) and 65 (2) months in those with nondilated NICD, respectively (p < 3 
0.001).  4 
NYHA functional class III or IV and renal insufficiency were strong predictors of 5 
mortality in both patient groups. The cumulative proportion of patients with renal impairment 6 
surviving at 6 years after implantation was 38%, compared with 89% among those with 7 
normal renal function (p < 0.001). The mean survival of patients with left ventricular ejection 8 
fraction 20% and below was 47 (SE, 8) months, compared with 92 (9) months of those with 9 
ejection fraction between 20% and 35% and 124 (5) months of those with ejection fraction > 10 
35%. However, left ventricular ejection fraction, ACE inhibitor / angiotensin receptor 11 
antagonist use and antiarrhythmic drug use was significantly associated with mortality risk 12 
only among patients with nondilated NICD, but not in those with DCM. Moreover, atrial 13 
fibrillation and a percentage of right ventricular pacing of 50% or more were strong predictors 14 
of mortality solely among patients with nondilated NICD. Patients with recurrent arrhythmias 15 
requiring ICD therapies were at higher risk of death than those who did not experience 16 
adequate ICD therapies.  17 
Estimated survival of subgroups according to indication for device implantation, age, 18 
renal function, left ventricular ejection fraction, NYHA functional class, occurrence of 19 
adequate ICD therapy, and underlying cardiac condition is presented in table 4 along with the 20 
life expectancy of age-matched Swiss population.[8]  21 
Multivariate Cox regression analysis was performed to identify factors which were 22 
independent predictors of mortality (Table 5). Reduced left ventricular ejection fraction and 23 
antiarrhythmic drug use (among patients with nondilated NICD) and higher NYHA functional 24 
class (among patients with DCM) were independently associated with an increased risk of 25 
 6 
death. ACE inhibitor / angiotensin receptor antagonist use (among patients with DCM) and 1 
occurrence of inappropriate ICD therapies (among patients with nondilated NICD) were 2 
associated with better outcome. Impaired renal function with eGFR below 60 ml/min/1.73m². 3 
was associated with higher risk in both patient groups and was the strongest independent 4 
predictor of mortality in the overall patient group. Adequate ICD therapy, the use of beta 5 
blockers, atrial fibrillation and ventricular pacing were not significantly associated with 6 
higher mortality in the multivariate model. 7 
Discussion 8 
This long-term observational study of patients with nonischemic cardiac disease implanted 9 
with an ICD demonstrated similar mortality rates (13%, 16% and 22% at 2, 4 and 5 years) as 10 
those of published randomized ICD trials of patients with nonischemic heart disease. The 11 
Cardiomyopathy Trial (CAT), which was a randomized ICD trial of  patients with dilated 12 
cardiomyopathy with left ventricular ejection fraction below 30% that was terminated 13 
prematurely, showed a 2-year mortality rate in the ICD arm of 8% and a 4-year mortality rate 14 
of 20%.[3] In the DEFINITE trial, which included patients with nonischemic CMP, left 15 
ventricular ejection fraction below 36%, and frequent premature ventricular complexes or 16 
non-sustained ventricular tachycardia, the 2-year mortality rate was 7.9% in the ICD-arm and 17 
14.1% in the standard-therapy arm.[4] Among patients with nonischemic chronic heart failure 18 
in the SCD-HeFT trial, 5-year mortality was 21% in the ICD-group and 28% in the placebo 19 
group.[5]  20 
Among patients who had been implanted with an ICD for primary prevention of SCD, 21 
mortality was higher during the first two years after device implantation compared to those 22 
with a secondary prevention indication, irrespective of underlying cardiac condition. This 23 
likely reflects the high risk associated with more reduced left ventricular ejection fraction, 24 
 7 
higher NYHA functional class and worse renal function in the primary prevention group. 1 
However, long-term mortality was similar after 6 years among both patient groups. 2 
Interestingly, a similar survival curve with high initial mortality during the first year after 3 
device implantation has been recently demonstrated by Parkash et al. in ICD patients who 4 
were classified as being at high risk by use of a clinical risk score.[9] 5 
Advanced age was associated with shorter survival time. Although patients younger 6 
than 55 years had significantly better survival compared with those who were older than 55 7 
years, age was only weakly associated with adverse outcome in patients older than 55 years. 8 
Most randomized trials have not specifically addressed the very elderly. In the CIDS study, 9 
which included patients with ejection fraction < 35%, age ≥ 70 years was an indicator of high 10 
risk, and patients at highest risk of death benefited most from ICD therapy.[10] Our data 11 
suggest that these patients may benefit from an ICD unless device implantation is 12 
contraindicated on the ground of life-limiting comorbidities. Correspondingly, a recent study 13 
of elderly patients, of which 20% had nonischemic cardiac disease, demonstrated a median 14 
survival greater than 4 years among octogenarian ICD recipients.[11] These results indicate 15 
the importance of individualized decisions to implant an ICD, which must take into account 16 
overall quality of life and expected life span after implant.  17 
We found several clinical factors to be related with long-term mortality after 18 
implantation of an ICD. Both atrial fibrillation and right ventricular pacing were associated 19 
with higher risk among patients with nondilated NICD. The incidence of atrial fibrillation is 20 
increased in patients with advanced age and in those with structural heart disease. Adverse 21 
prognosis with atrial fibrillation may result from multiple factors, including heart failure, 22 
stroke, and drug toxicity.[12] Additionally, atrial fibrillation may increase the risk of 23 
ventricular tachyarrhythmias.[13] Left bundle branch block or a QRS width greater than 120 24 
ms, which are frequently used as surrogate markers of ventricular dyssynchrony, were not 25 
 8 
associated with an increased mortality risk. Electrical or mechanical ventricular dyssynchrony 1 
has been shown to be associated with adverse outcome[14;15] and serves as a 2 
pathophysiologic basis for cardiac resynchronization therapy. However, in our current study 3 
these surrogate markers did not reliably identify patients with higher risk, irrespective of 4 
underlying cardiac condition. On the other hand, the mortality risk of patients who were 5 
chronically paced from the right ventricle was increased, although this effect was not 6 
statistically significant among patients with DCM. Correspondingly, right ventricular pacing 7 
has been quantitatively associated with decreased survival in the DAVID trial.[16] 8 
Experiencing appropriate ICD therapies was an indicator of an increased mortality risk, 9 
whereas risk was low among patients who received inappropriate ICD therapies only. 10 
The use of antiarrhythmic drugs, ACE inhibitors or angiotensin receptor blockers was 11 
associated with increased mortality among patients with nondilated NICD, while betablocker 12 
use was not. Various effects of medical therapy on outcomes have been reported in ICD 13 
recipients. However, in the current study medical therapy was administered in an 14 
individualized manner according to the nature and severity of underlying diseases, and was 15 
adapted to the clinical needs of the patients throughout the follow-up period. Further analysis 16 
of associations with mortality risk may therefore not be warranted. 17 
Many of the clinical factors which were associated with adverse outcome were highly 18 
intercorrelated. Multivariate analysis identified six independent predictors of mortality, ie. left 19 
ventricular ejection fraction, NYHA functional class, ACE inhibitor / angiotensin receptor 20 
antagonist and antiarrhythmic drug use, and renal function. Reduced left ventricular ejection 21 
fraction has been recognised as an indicator of adverse prognosis for several years. NYHA 22 
functional class, which is subjective and may be influenced by non-cardiac factors, including 23 
body weight, overall fitness and comorbidities, adds independent prognostic information. In 24 
the current study, renal insufficiency was the strongest independent predictor of mortality in 25 
 9 
the overall group and was the only factor predicting mortality in both subgroups. This finding 1 
is in line with recent studies of mortality among ICD patients with renal insufficiency, which 2 
included primarily patients with ischemic cardiomyopathy.[17-19]  Impairment of renal 3 
function has been associated with increased risk of cardiovascular mortality in various 4 
studies. Although in some of those, associations lost significance after correction for 5 
traditional cardiovascular risk factors, Henry et al. demonstrated in a population-based study 6 
of 632 Caucasian individuals aged 50 to 75 years that mild to moderate reduction in renal 7 
function is associated with increased cardiovascular mortality without involving common risk 8 
factors such as hypertension, diabetes or hyperhomocysteinemia.[20] In patients with 9 
coronary disease and renal impairment, accelerated atherosclerosis, adverse left ventricular 10 
remodelling associated with erythropoietin deficiency and anemia, and hyperactivation of the 11 
renin angiotensin system may contribute to increased mortality. In patients with nonischemic 12 
cardiac disease other factors may be more important. Sympathetic overactivity and a higher 13 
propensity to cardiac arrhythmias that may be refractory to ICD treatment have been observed 14 
in chronic kidney disease, and elevated defibrillation thresholds may be found in these 15 
patients.[21-23] Furthermore, underuse of proven beneficial therapies as well as drug toxicity 16 
from therapies used may increase morbidity and mortality. 17 
Limitations 18 
This is a retrospective single-centre study, which suffers from limitations typically associated 19 
with this type of trial design. Data were collected retrospectively from the implantation 20 
reports and medical charts, and were therefore dependent on the accuracy of clinical 21 
documentation. Renal function and medical treatment was assessed at the time point of 22 
inclusion of the patient in the study. Serial reassessment throughout the study period, which 23 
would give more detailed information, was not available. The results of this single-center 24 
 10 
study might not be generalizable to other centers with different patient characteristics. 1 
However, our hospital not only serves as a tertiary referral center but also provides primary 2 
medical services to the population of Zurich, which may reduce referral bias. It should be kept 3 
in mind that nonischemic cardiac disease is not a homogenous entity. Outcomes are likely to 4 
vary according to underlying disease mechanisms and patient characteristics. The number of 5 
patients included in our study did not provide sufficient statistical power to allow for detailed 6 
subgroup analysis of patients with nondilated NICD by underlying cardiac disease. However, 7 
the distinction between ischemic and nonischemic cardiac disease is frequently used in 8 
clinical practice. Therefore the results of this study may be helpful to the clinician for 9 
estimation of the benefit of ICD therapy in patients with DCM and in those with other, 10 
nondilated NICD. 11 
Conclusion 12 
During long-term follow-up of ICD patients with DCM, higher NYHA functional class is 13 
associated with adverse outcome, whereas in patients with nondilated NICD reduced left 14 
ventricular ejection fraction and antiarrhythmic drug use predict higher mortality. Renal 15 
insufficiency is a strong predictor of mortality among all patients with NICD, irrespective of 16 
underlying heart disease. Additional studies are warranted to determine the impact of 17 
underlying cardiac disease on prognosis in this clinically important but heterogeneous patient 18 
group. 19 
 11 
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Figure Legend 
 
Figure 1. Survival curves of ICD patients with dilated cardiomyopathy (DCM, left panel) and 
with other NICD (right panel) 
 
Figure 2. Survival curves of ICD patients with nonischemic cardiac disease according to 
renal function. Upper panel: overall group. Mid panel: patients with nondilated NICD. Lower 
panel: patients with dilated cardiomyopathy. 
  
Primary 
prevention 
(n = 40) 
Secondary prevention 
(n = 136) 
Total 
(n = 176) 
Age, years 54 (11) 52 (15) 53 (14) 
Male sex 33 (83%) 105 (77%) 138 (78%) 
Left ventricular ejection fraction, % 30 (14) 43 (18) 40 (18) 
LVEF <35 % 31 (78%) 63 (46%) 94 (54%) 
NYHA functional class    
 NYHA I 4 (10%) 21 (15%) 25 (14%) 
 NYHA II 20 (50%) 85 (63%) 105 (60%) 
 NYHA III 15 (38%) 28 (21%) 43 (24%) 
 NYHA IV 1 (3%) 2 (2%) 3 (2%) 
Heart rate, beats x min-1 76 (18) 70 (17) 72 (18) 
Heart Rhythm    
 Sinus rhythm 27 (68%) 108 (79%) 135 (77%) 
 Atrial fibrillation 9 (23%) 13 (10%) 22 (13%) 
Right ventricular pacing 4 (10%) 15 (11%) 19 (11%) 
ECG ventricular conduction    
 Right bundle branch block - 11 ( 8%) 11 ( 6%) 
 Left bundle branch block 15 (38%) 25 (19%) 40 (23%) 
 Left anterior fascicular block 1 (3%) 12 (9%) 13 (8%) 
 Bifascicular Block 1 (3%) 2 (2%) 3 (2%) 
 QRS > 120 ms 19 (48%) 51 (38%) 70 (40%) 
Arterial Hypertension 5 (13%) 25 (18%) 30 (17%) 
Systolic blood pressure 109 (20) 120 (21) 117 (21) 
Diastolic blood pressure 71 (14) 73 (12) 73 (13) 
Hypotension (systolic BP < 100mmHg) 19 (48%) 24 (18%) 43 (24%) 
Diagnosis    
 Dilated CMP 26 (63%) 48 (36%) 74 (42%) 
 Hypertrophic CMP 3 (7%) 13 (10%) 16 (9%) 
 Arrhythmogenic right  
 ventricular CMP 1 (2%) 18 (13%) 19 (11%) 
 Non-compaction CMP 4 6 (4%) 10 (6%) 
 Idiopathic VT - 8 (6%) 8 (5%) 
 Brugada Syndrome 1 (2%) 4 (3%) 5 (3%) 
 Long QT Syndrome - 1 (1%) 1 (1%) 
 Congenital heart disease 1 (2%) 9 (7%) 10 (6%) 
 Unclassified / other 5 (12%) 28 (21%) 33 (19%) 
Family history of SCD 6 (15%) 19 (14%) 25 (14%) 
Diabetes mellitus 9 (23%) 8 (6%) 17 (10%) 
Chronic renal disease 11 (28%) 32 (24%) 43 (24%) 
Estimated GFR (ml x min-1 x 1.73m-2) 61 (19) 72 (19) 70 (20) 
Medical therapy    
 Beta blocker 34 (85%) 84 (62%) 118 (67%) 
 Amiodarone 1 (3%) 44 (32%) 45 (26%) 
 Sotalol - 4 (3%) 4 (2%) 
 ACEI / ARB 34 (85%) 80 (59%) 114 (65%) 
 
Table 1. Baseline characteristics according to primary or secondary prophylactic indication 
for ICD implantation. DCM = dilated cardiomyopathy. HCM = hypertrophic cardiomyopathy. 
ARVC = arrhythmogenic right ventricular cardiomyopathy. CMP = cardiomyopathy. VT = 
ventricular tachycardia. ACEI = ACE inhibitor. ARB = angiotensin receptor blocker. 
 Predictor Hazard ratio (95% CI) P value 
Age   
 < 55 years 1 - 
 55 - 70 years 4.15 (1.78-9.67) <0.001 
 > 70 years 6.39 (2.29-17.87) <0.001 
Male sex 4.16 (0.99-17.44) 0.05 
Secondary prevention ICD indication 2.20 (0.81-6.00) 0.12 
Heart Rhythm   
 Sinus rhythm 1 - 
 Atrial fibrillation 3.10 (1.27-7.58) 0.01 
 Right ventricular pacing 2.95 (1.20-7.21) 0.02 
QRS Electrocardiogram   
 No bundle branch block 1 - 
 Left bundle branch block 1.46 (0.63-3.43) 0.38 
 QRS width > 120 ms 1.83 (0.91-3.69) 0.09 
Family history of SCD 0.84 (0.29-2.41) 0.75 
Arterial hypertension 0.75 (0.29-1.95) 0.56 
Diabetes mellitus 1.56 (0.47-5.18) 0.47 
Renal insufficiency (eGFR < 60 ml/min/1.73m²) 6.50 (3.15-13.43) <0.001 
NYHA class ≥ 3 6.71 (3.12-14.46) <0.001 
LVEF < 35 % 4.91 (2.11-11.44) <0.001 
Beta blocker use 1.24 (0.59-2.61) 0.56 
Antiarrhythmic drug use 4.03 (1.94-8.37) <0.001 
ACEI / ARB use 2.72 (1.17-6.32) 0.02 
Adequate ICD therapy 2.35 (1.09-5.10) 0.03 
Inadequate ICD therapy 0.44 (0.19-1.04) 0.05 
Table 2. Univariate Cox Regression Analysis of Factors Predicting Mortality. 
 Predictor Hazard ratio (95% CI) P value 
NYHA class ≥ 3 2.52 (1.08-5.84) 0.03 
LVEF < 35 % 3.32 (1.37-8.03) 0.01 
Renal insufficiency 5.87 (2.48-13.86) <0.001 
 
Table 3.  Multivariate Cox Regression Analysis of Factors Predicting Mortality.  
Figure 1 
 
 
 
